Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes

被引:41
作者
Casellas, Alba [1 ]
Salavert, Ariana [1 ]
Agudo, Judith [1 ]
Ayuso, Eduard [1 ]
Jimenez, Veronica [1 ]
Moya, Marta [1 ]
Munoz, Sergio [1 ]
Franckhauser, Sylvie [1 ]
Bosch, Fatima [1 ]
机构
[1] Univ Autonoma Barcelona, Sch Vet Med, Ctr Anim Biotechnol & Gene Therapy, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain
关键词
D O I
10.2337/db06-0328
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetic patients are diagnosed when beta-cell destruction is almost complete. Reversal of type I diabetes will require D-cell regeneration from islet cell precursors and prevention of recurring autoimmunity. IGF-I expression in beta-cells of streptozotocin (STZ)-treated transgenic mice regenerates the endocrine pancreas by increasing P-cell replication and neogenesis. Here, we examined whether IGF-I also protects islets from autoimmune destruction. Expression of interferon (IFN)-beta in beta-cells of transgenic mice led to islet beta(2)-microglobulin and Fas hyperexpression and increased lymphocytic infiltration. Pancreatic islets showed high insulitis, and these mice developed overt diabetes when treated with very-low doses of STZ, which did not affect control mice. IGF-I expression in IFN-pexpressing beta-cells of double-transgenic mice reduced beta(2)-microglobulin, blocked Fas expression, and counteracted islet infiltration. This was parallel to a decrease in beta-cell death by apoptosis in islets of STZ-treated IGF-I+IFN-beta-expressing mice. These mice were normoglycemic, normoinsulinemic, and showed normal glucose tolerance. They also presented similar pancreatic insulin content and beta-cell mass to healthy mice. Thus, local expression of IGF-I prevented islet infiltration and beta-cell death in mice with increased susceptibility to diabetes. These results indicate that pancreatic expression of IGF-I may regenerate and protect beta-cell mass in type 1 diabetes.
引用
收藏
页码:3246 / 3255
页数:10
相关论文
共 45 条
[1]   IFNβ accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to β cells in nondiabetes-prone mice [J].
Alba, A ;
Puertas, MC ;
Carrillo, J ;
Planas, R ;
Ampudia, R ;
Pastor, X ;
Bosch, F ;
Pujol-Borrell, R ;
Verdaguer, J ;
Vives-Pi, M .
JOURNAL OF IMMUNOLOGY, 2004, 173 (11) :6667-6675
[2]   Type 1 diabetes: new perspectives on disease pathogenesis and treatment [J].
Atkinson, MA ;
Eisenbarth, GS .
LANCET, 2001, 358 (9277) :221-229
[3]   In vivo gene transfer to healthy and diabetic canine pancreas [J].
Ayuso, E ;
Chillón, M ;
García, F ;
Agudo, J ;
Andaluz, A ;
Carretero, A ;
Monfar, M ;
Moya, M ;
Montané, J ;
Otaegui, PJ ;
Bosch, F .
MOLECULAR THERAPY, 2006, 13 (04) :747-755
[4]   In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors [J].
Ayuso, E ;
Chillón, M ;
Agudo, J ;
Haurigot, V ;
Bosch, A ;
Carretero, A ;
Otaegui, PJ ;
Bosch, F .
HUMAN GENE THERAPY, 2004, 15 (08) :805-812
[5]   INSULIN-DEPENDENT DIABETES-MELLITUS AS AN AUTOIMMUNE-DISEASE [J].
BACH, JF .
ENDOCRINE REVIEWS, 1994, 15 (04) :516-542
[6]   Tolerance to islet autoantigens in type 1 diabetes [J].
Bach, JF ;
Chatenoud, L .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :131-161
[7]   PREVENTION OF DIABETES IN THE NOD MOUSE - IMPLICATIONS FOR THERAPEUTIC INTERVENTION IN HUMAN-DISEASE [J].
BOWMAN, MA ;
LEITER, EH ;
ATKINSON, MA .
IMMUNOLOGY TODAY, 1994, 15 (03) :115-120
[8]   Inhibitory effect of IGF-I on type 2 nitric oxide synthase expression in Ins-1 cells and protection against activation-dependent apoptosis -: Involvement of phosphatidylinositol 3-kinase [J].
Castrillo, A ;
Bodelón, OG ;
Boscá, L .
DIABETES, 2000, 49 (02) :209-217
[9]   Role of apoptosis in pancreatic β-cell death in diabetes [J].
Chandra, J ;
Zhivotovsky, B ;
Zaitsev, S ;
Juntti-Berggren, L ;
Berggren, PO ;
Orrenius, S .
DIABETES, 2001, 50 :S44-S47
[10]   β cell expression of IGF-I leads to recovery from type 1 diabetes [J].
George, M ;
Ayuso, E ;
Casellas, A ;
Costa, C ;
Devedjian, JC ;
Bosch, F .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) :1153-1163